Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $111
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $110 to $111.
February 21, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Ultragenyx Pharmaceutical and raises the price target to $111.
The maintenance of a Buy rating combined with a slight increase in the price target by a reputable analyst firm like Canaccord Genuity typically signals a positive outlook on the stock, suggesting potential short-term upward price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100